No Data
No Data
Tempest Therapeutics: Navigating Financial Challenges With Promising Clinical Data and Strategic Partnerships
Scotiabank Maintains Tempest Therapeutics(TPST.US) With Hold Rating, Maintains Target Price $9
Analysts' Opinions Are Mixed on These Healthcare Stocks: Tempest Therapeutics (TPST) and Astria Therapeutics (ATXS)
Tempest Therapeutics Reports Q1 EPS ($3.16), Consensus ($3.29)
Tempest Therapeutics | 10-Q: Q1 2025 Earnings Report
Tempest Therapeutics Reports Positive Amezalpat Data and FDA Designations for Cancer Treatment Programs